Merck & Co.
MRK
$152.55
+2.39%
Merck & Co., Inc. is a global healthcare leader that develops and manufactures pharmaceuticals, vaccines, and animal health products, with a focus on therapeutic areas including oncology, cardiometabolic disease, and infectious diseases. The company's competitive identity is anchored by its immuno-oncology franchise, led by the blockbuster drug Keytruda, and a robust vaccine portfolio including Gardasil and the newly expanded Capvaxive. Currently, the investor narrative centers on Merck's ability to navigate the looming patent cliff for Keytruda, while leveraging pipeline advancements and label expansions to sustain growth. Recent FDA approval for Capvaxive in at-risk children and teens, along with ongoing clinical trials, underscores the company's strategic push to diversify its revenue streams and mitigate future competitive pressures.…
MRK
Merck & Co.
$152.55
Related headlines
Investment Opinion: Should I buy MRK Today?
Based on the analysis, MRK is rated a Buy. The thesis is that Merck offers a rare combination of defensive characteristics (beta 0.211) and growth potential, with a 34% discount to the industry PE and a robust pipeline. The consensus recommendation is 'Buy' with an average target of $137.73, implying modest upside, but the high target of $155 suggests potential for significant gains if pipeline successes materialize.
Sign up to view all
MRK 12-Month Price Forecast
The AI assessment is bullish, driven by Merck's undervaluation relative to peers and its strong cash generation. The stock's low beta and defensive nature make it a suitable core holding, but the medium confidence reflects uncertainty around the Keytruda patent cliff. If the pipeline delivers positive results, the stance would be upgraded to high confidence, while a major pipeline failure would downgrade it to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Merck & Co.'s 12-month outlook, with a consensus price target around $146.54 and implied upside of -3.9% versus the current price.
Average Target
$146.54
0 analysts
Implied Upside
-3.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$105 - $179
Analyst target range
Merck is covered by 26 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.79 (where 1 is Strong Buy and 5 is Sell). The average price target is $137.73, implying a modest 1.39% upside from the current price of $135.84. The target price range spans from $105.00 (low) to $155.00 (high), reflecting a wide dispersion of expectations. The high target of $155 suggests analysts see potential for continued growth, possibly driven by pipeline successes and label expansions, while the low target of $105 implies concerns about the Keytruda patent cliff and competitive pressures. Recent ratings from major firms like BMO Capital, Guggenheim, and JP Morgan have maintained positive outlooks, indicating stable sentiment. The relatively tight spread between the average and current price suggests that the stock is fairly valued in the near term, but the wide range highlights uncertainty regarding long-term growth prospects.
Bulls vs Bears: MRK Investment Factors
Merck presents a compelling value proposition with a strong uptrend, undervaluation relative to peers, and robust cash flows, but faces significant overhangs from the Keytruda patent cliff and a leveraged balance sheet. The bull case is supported by a 34% PE discount and pipeline expansions, while the bear case centers on revenue concentration and the looming loss of exclusivity. Currently, the bull side has stronger evidence given the stock's momentum and valuation, but the key tension is whether Merck can successfully diversify before Keytruda's patent expiry. The resolution of this tension—through pipeline successes or label expansions—will determine the long-term thesis.
Bullish
- Strong momentum near 52-week high: MRK is trading at $135.84, just 0.1% below its 52-week high of $135.97, with a 1-year price change of +64.14% versus the S&P 500's +20.37%. This indicates robust investor confidence and a strong uptrend, supported by a beta of 0.211, making it a defensive growth pick.
- Undervalued on earnings and sales: The trailing PE is 14.42x and forward PE is 14.21x, a 34% discount to the industry average of 22x. The PS ratio of 4.06x is also below the sector average, suggesting the market is not fully pricing in Merck's growth potential and pipeline value.
- Robust free cash flow and margins: Merck generated $14.12 billion in trailing twelve-month free cash flow, with a gross margin of 71.98% and operating margin of 36.17%. These metrics indicate strong underlying profitability and cash generation, even after the one-time R&D charge in Q1 2026.
- Pipeline and label expansions: The FDA expanded Capvaxive's label to include at-risk children and teens, strengthening Merck's vaccine franchise against Pfizer. Additionally, ongoing trials and a diversified pipeline (oncology, vaccines) provide growth optionality beyond Keytruda.
Bearish
- Keytruda patent cliff looms: Keytruda, Merck's top-selling drug, faces patent expiration in the late 2020s, which could lead to significant revenue loss. The low analyst target of $105 reflects concerns about this cliff, and the stock's valuation may compress as the date approaches.
- Q1 2026 net loss due to R&D charge: Merck reported a net loss of -$4.24 billion in Q1 2026, driven by a massive $12.56 billion R&D charge. While likely one-time, such charges can signal acquisition or impairment risks, and the negative EPS of -$1.72 may spook investors.
- High debt-to-equity ratio: The debt-to-equity ratio stands at 0.96, indicating a leveraged balance sheet. This could limit financial flexibility and increase vulnerability to rising interest rates, though the current ratio of 1.54 provides some liquidity cushion.
- Modest near-term upside to target: The average analyst target of $137.73 is only 1.39% above the current price, suggesting limited near-term appreciation. This tight spread indicates the stock is fairly valued in the short term, with the wide range (105-155) reflecting high uncertainty.
MRK Technical Analysis
Merck's stock is in a strong uptrend, with a 1-year price change of +64.14%, significantly outperforming the S&P 500's +20.37% over the same period. The current price of $135.84 sits just 0.1% below its 52-week high of $135.97, indicating the stock is trading at the upper end of its 52-week range (99.9% of the range). This positioning suggests strong momentum and investor confidence, though it also raises the risk of short-term overextension. The stock's beta of 0.211 indicates it is significantly less volatile than the broader market, making it a defensive choice within the healthcare sector.
Beta
0.21
0.21x market volatility
Max Drawdown
-11.9%
Largest decline past year
52-Week Range
$78-$154
Price range past year
Annual Return
+77.2%
Cumulative gain past year
| Period | MRK Return | S&P 500 |
|---|---|---|
| 1m | +19.7% | +2.5% |
| 3m | +24.6% | +2.7% |
| 6m | +24.8% | +11.1% |
| 1y | +77.2% | +20.5% |
| ytd | +43.3% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MRK Fundamental Analysis
Merck's revenue trajectory shows moderate growth, with the most recent quarter (Q1 2026) reporting revenue of $16.29 billion, a 4.27% year-over-year increase. This growth is driven by the Pharmaceutical segment, which contributed $14.35 billion, while Animal Health added $1.79 billion. However, the company reported a net loss of -$4.24 billion in Q1 2026, primarily due to a massive $12.56 billion R&D charge, likely related to an acquisition or impairment. Excluding this one-time charge, the underlying profitability remains strong, as evidenced by the trailing twelve-month free cash flow of $14.12 billion and a gross margin of 71.98%. The company's balance sheet is solid, with a debt-to-equity ratio of 0.96 and a current ratio of 1.54, indicating adequate liquidity. Merck generated $3.92 billion in operating cash flow in Q1 2026, though this was impacted by the R&D charge, and it continues to return capital to shareholders via dividends and buybacks.
Quarterly Revenue
$16.3B
2026-03
Revenue YoY Growth
+4.3%
YoY Comparison
Gross Margin
81.9%
Latest Quarter
Free Cash Flow
$14.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MRK Overvalued?
Given that Merck's trailing twelve-month net income is positive (despite the Q1 loss), the price-to-earnings (PE) ratio is the most appropriate valuation metric. The trailing PE is 14.42x, while the forward PE is 14.21x, indicating that the market expects stable earnings growth. This is supported by a PEG ratio of 1.81, suggesting the stock is fairly valued relative to its growth rate. Compared to the industry average PE of 22x (based on sector data), Merck trades at a 34% discount, which is notable given its strong pipeline and market position. Historically, Merck's PE has ranged from 9x to 32x over the past few years, and the current 14.42x is near the lower end of that range, suggesting the stock may be undervalued relative to its own history. The price-to-sales ratio of 4.06x is also below the sector average, further supporting a value-oriented investment thesis.
PE
14.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 9x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high debt-to-equity ratio of 0.96, which could strain cash flows if interest rates rise, and the Q1 2026 net loss of -$4.24 billion due to a $12.56 billion R&D charge, which may indicate future impairments or acquisition costs. However, the company's free cash flow of $14.12 billion TTM and gross margin of 71.98% provide a strong buffer, and the current ratio of 1.54 suggests adequate short-term liquidity. The payout ratio of 44.79% indicates a sustainable dividend, but the negative EPS in Q1 could pressure future payouts if repeated.